microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Alrfaei, Bahauddeen M ^a   Vemuganti, Raghu ^a   Kuo, John S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN100 MICRORNA, HUMAN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR;

ANIMAL; CELL PROLIFERATION; DRUG SCREENING; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MOUSE; NICK END LABELING; PHYSIOLOGY; SCID MOUSE;

ANIMALS; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; MICRORNAS; NUCLEAR RECEPTOR CO-REPRESSOR 2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893582295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080865     Document Type: Article

References (49)

1. CBTRUS (2006) Primary Brain Tumors in the United States Statistical Report 1998-2002 Central Brain Tumor Registry of the United States
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu H-K, Wen PY et al. (2010) Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. CA Cancer J Clin 60: 166-193. doi:10.3322/caac.20069. PubMed: 20445000.
3. Sauvageot CME, Weatherbee JL, Kesari S, Winters SE, Barnes J et al. (2008) Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro-Oncology 11: 109-121. doi:10.1215/15228517- 2008-060. PubMed: 18682579.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. PubMed: 15758009. (Pubitemid 40349501)
5. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. doi:10.1056/NEJMoa043331. PubMed: 15758010. (Pubitemid 40349502)
6. Bartel DP (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell 136: 215-233. doi:10.1016/j.cell.2009.01.002. PubMed: 19167326.
7. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114. PubMed: 18197166.
8. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells. Cancer Res 65: 6029-6033. doi:10.1158/0008-5472.CAN-05-0137. PubMed: 16024602. (Pubitemid 40994386)
9. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R et al. (2008) microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma. Cancer Res 68: 3566-3572. doi:10.1158/0008-5472.CAN-07-6639. PubMed: 18483236.
10. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells. Cancer Res 68: 8164-8172. doi:10.1158/0008-5472.CAN-08-1305. PubMed: 18829576.
11. You S-H, Lim H-W, Sun Z, Broache M, Won K-J et al. (2013) Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat Struct Mol Biol 20: 182-187. doi:10.1038/nsmb.2476. PubMed: 23292142.
12. Xia H, Yan Y, Hu M, Wang Y, Wang Y et al. (2013) MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity. Neuro-Oncology 15: 413-422. doi:10.1093/neuonc/nos296. PubMed: 23243056.
13. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG et al. (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358. doi:10.1016/j.bbrc.2005.07.030. PubMed: 16039986. (Pubitemid 41074723)
14. Li Y, Guessous F, Zhang Y, DiPierro C, Kefas B et al. (2009) MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes. Cancer Res 69: 7569-7576. doi:10.1158/0008-5472.CAN-09-0529. PubMed: 19773441.
15. Wahid F, Shehzad A, Khan T, Kim YY (2010) MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta - Mol Cell Res 1803: 1231-1243. doi:10.1016/j.bbamcr.2010.06.013. PubMed: 20619301.
16. Srinivasan S, Patric IRP, Somasundaram K (2011) A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma. PLOS ONE 6: e17438. doi:10.1371/journal.pone.0017438. PubMed: 21483847.
17. Purow B (2011) The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? J Neuro Oncol 103: 429-436. doi:10.1007/s11060-010-0449-5. PubMed: 21082214.
18. Grundmann S, Hans FP, Kinniry S, Heinke J, Helbing T et al. (2011) MicroRNA-100 Regulates Neovascularization by Suppression of Mammalian Target of Rapamycin in Endothelial and Vascular Smooth Muscle Cells. Circulation 123: 999-1009. doi:10.1161/CIRCULATIONAHA.110.000323. PubMed: 21339483.
19. Liu J, Lu K-H, Liu Z-L, Sun M, De W et al. (2012) MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer 12: 519. doi:10.1186/1471-2407-12-519. PubMed: 23151088.
20. Silbergeld DL, Ali-Osman F, Winn HR (1991) Induction of transformational changes in normal endothelial cells by cultured human astrocytoma cells. J Neurosurg 75: 604-612. doi:10.3171/jns.1991.75.4.0604. PubMed: 1885978.
21. Westermark B, Pontén J, Hugosson R (1973) DETERMINANTS FOR THE ESTABLISHMENT OF PERMANENT TISSUE CULTURE LINES FROM HUMAN GLIOMAS. Acta Pathol Microbiol Scand A Pathology 81A: 791-805. PubMed: 4359449.
22. Su G, Meyer K, Nandini CD, Qiao D, Salamat S et al. (2006) Glypican-1 Is Frequently Overexpressed in Human Gliomas and Enhances FGF-2 Signaling in Glioma Cells. Am J Pathol 168: 2014-2026. doi:10.2353/ajpath.2006.050800. PubMed: 16723715. (Pubitemid 43825320)
23. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S et al. (2012) Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR targeted Inhibition. Neoplasia 14: 420-428. PubMed: 22745588.
24. Marionneau C, Carrasquillo Y, Norris AJ, Townsend RR, Isom LL et al. (2012) The Sodium Channel Accessory Subunit Nav beta 1 Regulates Neuronal Excitability through Modulation of Repolarizing Voltage-Gated K+ Channels. J Neurosci 32: 5716-5727. doi:10.1523/JNEUROSCI.6450-11.2012. PubMed: 22539834.
25. Case N, Thomas J, Sen B, Styner M, Xie Z et al. (2011) Mechanical Regulation of Glycogen Synthase Kinase 3β (GSK3β) in Mesenchymal Stem Cells Is Dependent on Akt Protein Serine 473 Phosphorylation via mTORC2 Protein. J Biol Chem 286: 39450-39456. doi:10.1074/jbc.M111.265330. PubMed: 21956113.
26. Vivanco I, Mellinghoff IK (2010) Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 22: 573-578. doi:10.1097/CCO. 0b013e32833edbdf. PubMed: 20739887.
27. Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K et al. (2005) 19F and 1H MRI detection of amyloid [beta] plaques in vivo. Nat Neurosci 8: 527-533. doi:10.1038/nn1422. PubMed: 15768036. (Pubitemid 41007572)
28. Lee JH, Silva AC, Merkle H, Koretsky AP (2005) Manganese-enhanced magnetic resonance imaging of mouse brain after systemic administration of MnCl2: Dose-dependent and temporal evolution of T1 contrast. Magn Reson Med 53: 640-648. doi:10.1002/mrm.20368. PubMed: 15723400. (Pubitemid 40332285)
29. van Dierendonck JH, Keijzer R, van de Velde CJH, Cornelisse CJ (1989) Nuclear Distribution of the Ki-67 Antigen during the Cell Cycle: Comparison with Growth Fraction in Human Breast Cancer Cells. Cancer Res 49: 2999-3006. PubMed: 2720660. (Pubitemid 19148639)
30. Zorniak M, Clark PA, Leeper HE, Tipping MD, Francis DM et al. (2012) Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival. Clin Cancer Res 18: 3628-3636. doi:10.1158/1078-0432.CCR-12-0339. PubMed: 22589395.
31. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828. PubMed: 14522905. (Pubitemid 37187480)
32. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956. doi:10.1038/onc.2008.19. PubMed: 18297114. (Pubitemid 351913636)
33. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021. doi:10.1158/0008-5472.CAN-04-1364. PubMed: 15466194. (Pubitemid 39331011)
34. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A et al. (2010) Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 107: 6982-6987. doi:10.1073/pnas.1002472107. PubMed: 20351277.
35. Guo D, Prins RM, Dang J, Kuga D, Iwanami A et al. (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2: ra82-: ra82 PubMed: 20009104.
36. Pickering MT, Stadler BM, Kowalik TF (2008) miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene 28: 140-145. PubMed: 18836483.
37. Lee YS, Dutta A (2006) MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 7: 560-564. PubMed: 16784027. (Pubitemid 43891035)
38. Khanim FL, Gommersall LM, Wood VHJ, Smith KL, Montalvo L et al. (2004) Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 23: 6712-6725. doi:10.1038/sj.onc.1207772. PubMed: 15300237. (Pubitemid 39280003)
39. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ et al. (2010) Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability. Cancer Cell 18: 436-447. doi:10.1016/j.ccr.2010.10.022. PubMed: 21075309.
40. Watson PJ, Fairall L, Santos GM, Schwabe JWR (2012) Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 481: 335-340. PubMed: 22230954.
41. Zhu J, Wan H, Xue C, Jiang T, Qian C et al. (2013) Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration. Brain Res 1520: 15-22. doi:10.1016/j.brainres.2013. 04.061. PubMed: 23685192.
42. Hercbergs AH, Davis PJ, Davis FB, Ciesielski MJ, Leith JT (2009) Radiosensitization of GL261 glioma cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 2586-2591. doi:10.4161/cc.8.16.9328. PubMed: 19597333.
43. Snowden AW, Zhang L, Urnov F, Dent C, Jouvenot Y et al. (2003) Repression of Vascular Endothelial Growth Factor A in Glioblastoma Cells Using Engineered Zinc Finger Transcription Factors. Cancer Res 63: 8968-8976. PubMed: 14695215. (Pubitemid 38064078)
44. Campos B, Bermejo JL, Han L, Felsberg J, Ahmadi R et al. (2011) Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102: 387-392. doi:10.1111/j.1349-7006.2010.01792. x. PubMed: 21143702.
45. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS (2011) Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 17: 103-112. PubMed: 20957337.
46. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim H-J et al. (2007) SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 450: 415-419. doi:10.1038/nature06270. PubMed: 17928865. (Pubitemid 350126746)
47. Froud SJ (1999) The development, benefits and disadvantages of serum-free media. Dev Biol Stand 99: 157-166. PubMed: 10404887.
48. Bottenstein JE, Sato GH (1979) Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci USA 76: 514-517. doi:10.1073/pnas.76.1.514. PubMed: 284369. (Pubitemid 9106659)
49. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403. doi:10.1016/j.ccr.2006.03.030. PubMed: 16697959. (Pubitemid 43668737)